Vivos Inc (RDGL)

$0.08 0.00 (-1.53%)
Market Cap 38.68M
Revenue (ttm) 30,000.00
Net Income (ttm) -2.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,700.00%
Debt to Equity Ratio 0.00
Volume 213,984
Avg Vol 579,176
Day's Range N/A - N/A
Shares Out 455.54M
Stochastic %K 76%
Beta -0.56
Analysts Strong Buy
Price Target N/A

Company Profile

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. The company develops an yttrium-90 based precision radionuclide therapy device; RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing a universal laboratory cooling device; hydro...

Industry: Medical Devices
Sector: Healthcare
Phone: 509 222 2222
Address:
1030 N Center Parkway, Suite N288, Kennewick, United States
Bigginfishnchips
Bigginfishnchips Mar. 2 at 1:40 PM
$RDGL
0 · Reply
UWB67
UWB67 Mar. 2 at 12:10 PM
$RDGL The Company [Vivos] has plans to submit the IDE by the end of the first quarter [MARCH 2026] or in APRIL [2026]." - 10 February 2026 Vivos PR. "We [Vivos] continue to work toward anticipated DCGI [India] regulatory clearance later this quarter [MARCH 2026] to proceed with an expanded phase of therapy." - 3 February 2026 Vivos PR. 💪👏🙌🤞 GO VIVOS GO!
0 · Reply
6591Bling
6591Bling Mar. 1 at 11:25 PM
$RDGL When is the next Reverse Split>> DIRE FINANCIAL Need for Capital: As of the end of 2025, Vivos (RDGL) is operating with extremely limited capital, reporting about $0.05 million in revenue. Not a chance for FDA approval in the future, due to severe leakage containment issues, but to move forward with human clinical trials and address FDA feedback, the company requires significant funding. Stock Performance: As of late February 2026, the stock was trading in the $0.08 range. Low-priced stocks, as you know, on the OTC exchange usually demand reverse splits to increase share price. Key Risk Factor: The FDA's decision to decline the Investigational Device Exemption (IDE) for human trials in August 2025 means the company needs to raise funds not just for trials, but also to address the regulatory requirements, which increases the pressure for capital.
1 · Reply
Lochlank
Lochlank Feb. 28 at 5:38 PM
$RDGL coming here purely just to hate on daybyday5 if you are seeing this you should touch grass bag holder (she blocked me)
1 · Reply
Doccjc62
Doccjc62 Feb. 28 at 4:22 PM
$RDGL I see plenty to like with RDGL: Strong shot at FDA IDE approval for RadioGel, thanks to expert FDA consultant guidance boosting the odds. DCGI decision in India expected soon (likely March), opening doors for more human data and U.S. progress. IsoPet gaining momentum: massive growth (800–1,200% YoY in 2025), over 100 safe therapies across species (zero serious adverse events), 17+ clinics expanding, could go cash-flow positive soon. PrecisionGel tech has huge upside beyond current uses (anti-cancer, gene therapy, timed release), with fresh patents strengthening the IP. Quite a bit of upside potential in this stock .
1 · Reply
LiCka_LoLLiStiCk
LiCka_LoLLiStiCk Feb. 28 at 12:43 AM
$RDGL Nothing but accumulation since 1st week of December. We have to stay above $.08 for the purpose of the Reg A. IMO once we’ve completed it or we’re satisfied with a lesser amount we’ll take a ride north.
0 · Reply
anderson800
anderson800 Feb. 26 at 6:23 PM
$RDGL nobody is budging today. LOL
3 · Reply
Doccjc62
Doccjc62 Feb. 26 at 4:15 PM
$RDGL Pretty obvious who the paid bashers on this board are. Commenting on the $ amount traded is all she has . IDE submission in March or April . DCGI in March . IsoPet nearing profitability, and let’s not forget the PrecisionGel potential. Daybyday5(Sasha) , you should find a new stock to bash .
1 · Reply
UWB67
UWB67 Feb. 26 at 3:10 PM
$RDGL "The Company has plans to submit the IDE by the end of the first quarter or in April [2026]." - 10 February 2026 Vivos PR. "We continue to work toward anticipated DCGI [India] regulatory clearance later this quarter [2026] to proceed with an expanded phase of therapy." - 3 February 2026 Vivos PR. 💪👏🙌🤞 GO VIVOS GO!!!!!
0 · Reply
Daybyday5
Daybyday5 Feb. 26 at 3:09 PM
$RDGL $18 worth of trading by 10am
0 · Reply
Latest News on RDGL
No data available.
Bigginfishnchips
Bigginfishnchips Mar. 2 at 1:40 PM
$RDGL
0 · Reply
UWB67
UWB67 Mar. 2 at 12:10 PM
$RDGL The Company [Vivos] has plans to submit the IDE by the end of the first quarter [MARCH 2026] or in APRIL [2026]." - 10 February 2026 Vivos PR. "We [Vivos] continue to work toward anticipated DCGI [India] regulatory clearance later this quarter [MARCH 2026] to proceed with an expanded phase of therapy." - 3 February 2026 Vivos PR. 💪👏🙌🤞 GO VIVOS GO!
0 · Reply
6591Bling
6591Bling Mar. 1 at 11:25 PM
$RDGL When is the next Reverse Split>> DIRE FINANCIAL Need for Capital: As of the end of 2025, Vivos (RDGL) is operating with extremely limited capital, reporting about $0.05 million in revenue. Not a chance for FDA approval in the future, due to severe leakage containment issues, but to move forward with human clinical trials and address FDA feedback, the company requires significant funding. Stock Performance: As of late February 2026, the stock was trading in the $0.08 range. Low-priced stocks, as you know, on the OTC exchange usually demand reverse splits to increase share price. Key Risk Factor: The FDA's decision to decline the Investigational Device Exemption (IDE) for human trials in August 2025 means the company needs to raise funds not just for trials, but also to address the regulatory requirements, which increases the pressure for capital.
1 · Reply
Lochlank
Lochlank Feb. 28 at 5:38 PM
$RDGL coming here purely just to hate on daybyday5 if you are seeing this you should touch grass bag holder (she blocked me)
1 · Reply
Doccjc62
Doccjc62 Feb. 28 at 4:22 PM
$RDGL I see plenty to like with RDGL: Strong shot at FDA IDE approval for RadioGel, thanks to expert FDA consultant guidance boosting the odds. DCGI decision in India expected soon (likely March), opening doors for more human data and U.S. progress. IsoPet gaining momentum: massive growth (800–1,200% YoY in 2025), over 100 safe therapies across species (zero serious adverse events), 17+ clinics expanding, could go cash-flow positive soon. PrecisionGel tech has huge upside beyond current uses (anti-cancer, gene therapy, timed release), with fresh patents strengthening the IP. Quite a bit of upside potential in this stock .
1 · Reply
LiCka_LoLLiStiCk
LiCka_LoLLiStiCk Feb. 28 at 12:43 AM
$RDGL Nothing but accumulation since 1st week of December. We have to stay above $.08 for the purpose of the Reg A. IMO once we’ve completed it or we’re satisfied with a lesser amount we’ll take a ride north.
0 · Reply
anderson800
anderson800 Feb. 26 at 6:23 PM
$RDGL nobody is budging today. LOL
3 · Reply
Doccjc62
Doccjc62 Feb. 26 at 4:15 PM
$RDGL Pretty obvious who the paid bashers on this board are. Commenting on the $ amount traded is all she has . IDE submission in March or April . DCGI in March . IsoPet nearing profitability, and let’s not forget the PrecisionGel potential. Daybyday5(Sasha) , you should find a new stock to bash .
1 · Reply
UWB67
UWB67 Feb. 26 at 3:10 PM
$RDGL "The Company has plans to submit the IDE by the end of the first quarter or in April [2026]." - 10 February 2026 Vivos PR. "We continue to work toward anticipated DCGI [India] regulatory clearance later this quarter [2026] to proceed with an expanded phase of therapy." - 3 February 2026 Vivos PR. 💪👏🙌🤞 GO VIVOS GO!!!!!
0 · Reply
Daybyday5
Daybyday5 Feb. 26 at 3:09 PM
$RDGL $18 worth of trading by 10am
0 · Reply
Doccjc62
Doccjc62 Feb. 26 at 4:14 AM
$RDGL Sure feels like this is ready to run. Lots of upcoming near term catalysts. I've been adding on any pullbacks and will continue to do so.
2 · Reply
UWB67
UWB67 Feb. 25 at 11:54 AM
$RDGL
0 · Reply
TradingTomo
TradingTomo Feb. 25 at 3:24 AM
$RDGL
0 · Reply
infodeep
infodeep Feb. 25 at 1:07 AM
$RDGL "In parallel, the Company is engaged in discussions with experienced radiopharmaceutical contract manufacturers in India regarding the establishment of an international production facility." - Radiogel is so small, isn't this running the risk of IP theft? Companies in India could clone this tech and there would be no consequences, no one to sue or no way to protect your secrets. Competitors in foreign spaces could push RDGL out easily if they produced this themselves. The company will kill itself by not being cautious or well versed in foreign law.
2 · Reply
Bigginfishnchips
Bigginfishnchips Feb. 24 at 10:48 PM
$RDGL
0 · Reply
Den44
Den44 Feb. 24 at 5:39 PM
$RDGL 💥
2 · Reply
Daybyday5
Daybyday5 Feb. 24 at 5:12 PM
$RDGL so at current average volume it’ll take 3 months to close the offering 😭 hopefully this will coincide with ide approval and then new offering🥴
0 · Reply
UWB67
UWB67 Feb. 24 at 3:14 PM
$RDGL
0 · Reply
Fireballmillionaire
Fireballmillionaire Feb. 24 at 2:49 PM
$RDGL
0 · Reply
Aerovestorman
Aerovestorman Feb. 24 at 11:46 AM
$RDGL The effects of radiation, specifically Beta particles, is essentially the same on living, cancerous cells. The previous post below is a Red Herring. There is no point to assessing external stimulus the same as internal, metabolic stimulus. Someone is reaching…….again.
1 · Reply
6591Bling
6591Bling Feb. 24 at 5:57 AM
$RDGL just because a medical treatment works in animals is it guaranteed to work in humans? Df+6 No, it is not guaranteed that a medical treatment that works in animals will work in humans. In fact, the vast majority of drugs that show promise in animal studies fail to work or are unsafe when tested in human clinical trials. O Studies indicate that approximately 90% to 95% of drugs that pass animal tests fail in human trials. PETA +2 Here is a breakdown of why animal studies do not translate directly to human success: • Physiological Differences: Humans and animals differ significantly in metabolism, physiology, and anatomy. A compound that is non-toxic to a mouse or dog may be highly toxic to a human, and vice versa. • Disease Representation: Diseases in animal studies are often artificially induced in labs to mimic human symptoms, but they rarely capture the full complexity of the human condition.
6 · Reply
Aerovestorman
Aerovestorman Feb. 24 at 1:47 AM
$RDGL “Isopet” will realize success standing alone. However, the secondary exposure risk will apply to both because the dosimetry doesn’t care if you are a dog, cat or fat Albanian living in Costa Rica. Dude quit reaching for negativity just to throw a turd into a punch bowl. Just go away and make millions if you’re not going to invest. Stop sounding like snotty teenager.
0 · Reply